Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: HIV-Associated Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

Welcome to The Lymphoma Channel

Lymphoma is common among HIV positive patients with 60-200-fold increased risk of non-Hodgkin’s lymphoma and an 8-fold increased risk of Hodgkin’s lymphoma compared to the average population.

Most lymphomas in HIV positive patients are aggressive B-cell lymphomas. The common lymphomas include diffuse large B-cell lymphoma, primary CNS lymphoma and Burkitt’s lymphoma.

HIV associated lymphoma involves a complex interaction of the immune system particularly cytokine production, genetic aberrations, antigen stimulation and oncogenic viruses such as Epstein Barr Virus (EBV). The introduction of combination antiretroviral therapy has led to a reduction in HIV-associated lymphomas. This is many due to improvement in immune function.

View Lymphoma Overview Page